相关实验视频

Updated: Sep 14, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

针对晚期肺部类癌的第一线治疗疗法的有效性:现实世界的分析

K Amrane¹, B Cabarrou², G Justeau³

¹Drug Development Department, Institut Gustave-Roussy, Villejuif, France; Oncology Department, CH Morlaix, Morlaix, France.

|July 24, 2025

概括

一线免疫检查点抑制剂 (ICI),有或没有化疗,显著改善了晚期肺肉类瘤 (PSC) 的存活率. 这种治疗为这种罕见的非小细胞肺癌亚型提供了更好的预后.

科学领域:

在瘤学瘤学.
肺部病理学肺部病理学
医学经济学医学经济学

背景情况:

肺肉类瘤 (PSC) 是一种罕见的,攻击性的非小细胞肺癌亚型,对它的了解有限.
评估晚期PSC (APSC) 的治疗疗效对于改善患者的治疗结果至关重要.

研究的目的:

评估一线免疫检查点抑制剂 (ICI) 与化学疗法 (ChT) 或没有化学疗法 (ChT) 的疗效,与晚期PSC患者单独的化学疗法相比.
确定基于ICI的疗法对无进展生存 (PFS) 和整体生存 (OS) 的影响.

主要方法:

法国ESME-LC数据库 (2015-2022) 的回顾性分析,包括229名晚期PSC患者.
倾向性评分权重被用于间接比较一线ICI±ChT和单独ChT之间的结果.
分析了患者的关键特征,分子测试和PD-L1表达.

主要成果:

与单独的慢性治疗相比,一线ICI ± ChT显示PFS (4.6个月) 和OS (20.6个月) 的中位数显著更长 (PFS 2.2个月,OS 6.8个月).
危险比率表明ICI±ChT和改善的PFS (HR 0.46) 和OS (HR 0.46) 与单独ChT之间存在显著的关联.
在35.4%的受试患者中发现了包括KRAS突变在内的分子异常,在68.6%的患者中发现了高PD-L1表达 (≥50%).

结论:

一线ICI±ChT显著改善了晚期肺部肉类瘤的无进展和整体存活率.
这种现实世界的证据表明,基于ICI的疗法对先进的PSC具有相当大的预后益处.
对PSC的向疗法和生物标志物的进一步研究是有必要的.

关键词:

在NSCLCLC中,我们可以看到.在PD-L1中.化学疗法化疗化疗免疫疗法免疫疗法肺部肉类瘤的癌症.

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...